CMS issues guidance on IMD treatment option for substance use disorders
The Centers for Medicare & Medicaid Services yesterday released guidance for state Medicaid agencies implementing Section 5052 of the SUPPORT for Patients and Communities Act of 2018, which gives states the option to cover substance use disorder treatment and withdrawal management services for adults who reside primarily in an eligible institution for mental diseases. The guidance provides information on the new state plan option, including requirements related to beneficiary and provider eligibility, clinical screenings, continuum of care, care transitions, and maintenance of existing expenditures.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services is launching a new initiative for state Medicaid programs to purchase prescription drugs at prices aligned…
Headline
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed…
Headline
A Health Affairs study published Nov. 3 examined an increase in states banning prior authorizations in private insurance plans for opioid use disorder…
Headline
A report by the Department of Health and Human Services Office of the Inspector General found that many Medicare Advantage and Medicaid managed care plans…
Headline
A JAMA study published yesterday analyzed the health characteristics of individuals projected to lose Medicaid coverage due to work requirements included in…
Headline
The Centers for Medicare & Medicaid Services Sept. 30 released guidance to states clarifying its interpretation of a provision that…